481 related articles for article (PubMed ID: 34842621)
1. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
2. Antibody Conjugates-Recent Advances and Future Innovations.
Leung D; Wurst JM; Liu T; Martinez RM; Datta-Mannan A; Feng Y
Antibodies (Basel); 2020 Jan; 9(1):. PubMed ID: 31936270
[TBL] [Abstract][Full Text] [Related]
3. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
4. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
5. Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
Sau S; Alsaab HO; Kashaw SK; Tatiparti K; Iyer AK
Drug Discov Today; 2017 Oct; 22(10):1547-1556. PubMed ID: 28627385
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Peng H
Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
[TBL] [Abstract][Full Text] [Related]
8. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
11. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
12. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
[TBL] [Abstract][Full Text] [Related]
13. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
14. Advances and Limitations of Antibody Drug Conjugates for Cancer.
Mckertish CM; Kayser V
Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076
[TBL] [Abstract][Full Text] [Related]
15. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
Sheyi R; de la Torre BG; Albericio F
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
[TBL] [Abstract][Full Text] [Related]
16. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
[TBL] [Abstract][Full Text] [Related]
18. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
19. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
20. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
López de Sá A; Díaz-Tejeiro C; Poyatos-Racionero E; Nieto-Jiménez C; Paniagua-Herranz L; Sanvicente A; Calvo E; Pérez-Segura P; Moreno V; Moris F; Ocana A
J Hematol Oncol; 2023 Dec; 16(1):118. PubMed ID: 38087293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
